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Therapeutic challenge: severe dyspnea  
in a patient with metastatic breast cancer 
and lymphangitis carcinomatosis syndrome
Abstract
Introduction. Dyspnea, regardless of etiology (pulmonary, neuromuscular or caused by other factors), 
remains a significant challenge. There is still a lack of effective methods of the treatment of severe dyspnea 
associated with intensifying anxiety which is the most common indication for intensification of causative 
and symptomatic treatment or palliative sedation.
Case report. A 48 year-old woman diagnosed with relapsed breast cancer with bone, pleural, hepatic 
and pulmonary metastases with lymphangitis carcinomatosis syndrome confirmed by lung biopsy. In 2011 
the patient underwent breast conserving surgery followed by teletherapy, brachytherapy and tamoxifen 
hormone therapy for 5 years. Comorbidities included chronic obstructive pulmonary disease, diabetes 
mellitus type 2, depression and nicotine addiction.
The patient was urgently admitted to the Department of Oncology and Radiotherapy from Clinical 
Emergency Department due to rapidly aggravating dyspnea and respiratory failure. Chest X-ray showed 
massive bilateral pleural effusion and threatening cardiac tamponade. Treatment involved thoracentesis 
and pericardiocentesis with concurrent symptomatic management. After temporary stabilization of the 
patient and due to rapid progression of the disease salvage, paclitaxel chemotherapy was started. Despite 
the features of potential chemosensitivity (chemotherapy–naïve, rapid progression, visceral metastases) 
the applied treatment was ineffective. After careful evaluation of clinical situation and possible treatment 
strategies, and after obtaining patient’s consent, sedation with midazolam and morphine was applied.
Conclusions. This case demonstrated ineffective salvage chemotherapy used in the patient with severe dyspnea in-
duced by a rapid progression of metastatic breast cancer and difficulties in obtaining effective symptomatic treatment.
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Introduction
Dyspnea is often described by patients as suffo-
cating, choking or shortness of breath [1].In cancer 
patients, it can be caused by different mechanisms 
such as airways obstruction, loss of functional pulmo-
nary tissue (for example due to multiple metastases), 
presence of fluid — both in bronchoalveolar tract and 
in pleural cavity, pulmonary embolism or as a conse-
quence of lymphangitis carcinomatosis syndrome. 
Breathlessness exerts a major impact on patients’ and 
caregivers’ quality of life and generates higher distress 
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than pain or fatigue [1]. We present a patient with 
severe breathlessness and accompanying lymphangitis 
carcinomatosis. The first female patient with dissem-
inated uterus cancer was depicted by French pathol-
ogist Gabriel Andral in 1824, followed by Virchow in 
1855, Bristowe in 1868, a Reynaud in 1874 [2] and 
the term lymphangitis carcinomatosis was introduced 
by Troisier in 1873 to describe diffuse infiltration of 
the lymphatics of both the lungs by malignant cells 
[3]. In most cases this clinical condition is related to 
variety of symptoms, with dominating occurrence of 
dyspnea [4].
The case depiction
A 48 year-old woman with luminal A breast cancer, 
in 2011 patient underwent breast conserving surgery 
followed by teletherapy, brachytherapy and tamoxifen 
hormonotherapy. Comorbidities included chronic ob-
structive pulmonary disease (COPD) stage 3 category 
B GOLD classification, diabetes mellitus type 2, and 
depression. The patient was also a former smoker.
First symptoms of cancer relapse were fatigue, 
slow progression of dyspnea and condition deteri-
oration that occurred 3 months before respiratory 
failure. At that moment the patient was admitted 
to Pneumonology Department and the COPD dete-
rioration was suspected. It should be pointed that 
patient’s general condition was good according to 
Eastern Cooperative Oncology Group (ECOG) 0 across 
previous years with the excellent control of all co-
morbidities. After chest computed tomography (Fig. 
1–3) and spirometry the initial diagnosis was rejected. 
Results shown multiple pulmonary, pleural, hepatic, 
and bone metastases. The lung biopsy was performed 
and histopathological diagnosis of lymphangitis carci-
nomatosis (Fig. 5 A and B) was established. Additional 
immunochemistry was performed which confirmed 
relapse of breast cancer. 
At the time of relapse, the patient encountered 
acute stress reaction, confirmed by psychiatrist consul-
tation. Adequate treatment with sertraline, diazepam 
and psychological support was introduced; however, 
the expected effects were not obtained. Initially, the 
patient refused any anticancer treatment due to poor 
psychological condition.
Twelve weeks from the diagnosis of recurrence 
the patient was admitted to the Clinical Emergency 
Department with severe dyspnea and respiratory 
failure. Performance status according to ECOG was 
assessed as 4. Physical examination confirmed tachy-
pnoea, tachycardia, and hypertension associated with 
dyspnea and anxiety. Auscultation of lungs revealed 
bilateral muting over the lower pulmonary fields and 
Figure 1. Computed Tomography (CT) scan showing 
liver metastases
Figure 2. CT scan — local recurrence in the site of 
breast amputation
Figure 3. CT scan — visible characteristic presentation of 
lymphangitis carcinomatosa syndrome — ‘tree in bud’
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significantly increased in both pleural cavities. The 
V-Scan ultrasonography showed significant amount 
of fluid in pericardial sac, up to 24 mm behind right 
ventricle and right atrium; yet, still without the clinical 
manifestation of tamponade. The patient underwent 
right thoracentesis under local anaesthesia. Six hun-
dred mL of bloody tinted fluid was evacuated and 
further drainage was planned. The procedure was 
complicated by clinically insignificant pneumothorax.
The next day patient was moved to Oncology and 
Radiotherapy Department for symptomatic and (if 
possible) palliative anticancer treatment. Symptomatic 
treatment consisted of oxygen, corticosteroids and 
betamimetics in nebulization, prednisone or dexa-
methasone orally, acetylcysteine intravenously (IV). 
The pain was effectively managed with paracetamol 
IV, morphine administered subcutaneously (SC) as 
needed and transdermal buprenorphine. Additionally, 
the patient received furosemide and amoxicillin/clavu-
lanic acid IV, and pantoprazole orally. Unfortunately, 
further escalation of symptoms and poor overall status 
indicated that hydrothorax was not an individual cause 
of dyspnea and deterioration of performance status.
Heart function reassessment with V-scan ultra-
sonography was conducted and clinically significant 
pericardial tamponade was revealed; hence, the pa-
tient was transferred to Cardio-Surgery Department 
for additional procedures. Pericardiocentesis and left 
pleural cavity drainage were conducted which partially 
alleviate the symptoms. Overall status was stabilized 
(ECOG 3) for a few days. Although a slight improve-
ment in symptom intensity was observed, further 
treatment was still required.
Four days after cardiosurgical intervention salvage 
chemotherapy was started in accordance with the 
oncological board decision. This decision was based 
on the clinical factors that suggested potential che-
mosensitivity of cancer, patients age and will. The first 
cycle of paclitaxel chemotherapy (total dose per cycle 
100 mg) was administered along with premedication 
including dexamethasone, clemastine, and ondan-
setron. While early tolerance of chemotherapy was 
good, further days showed that the treatment was 
ineffective, and the patient’s  general status deteri-
orated quickly. Symptom burden, especially intense 
dyspnea, were unacceptable and lead to the extremely 
high level of anxiety, as the patient was fully conscious 
and aware of impending death. With the support of 
clinical psychologist possible treatment was discussed 
and the options were proposed to the patient and 
her family. Sedation has been chosen and informed 
consent to the procedures was given by the patient.
Morphine and midazolam in continuous intrave-
nous infusion were used with the expected positive 
Figure 4. Chest X-Ray - pulmonary edema
Figure 5 A–B. histopathological samples acquired from 
lung — HE stain — visible cancer cells in lung capillaries
bilateral crackles. Chest X-ray (Fig. 4) revealed bilateral 
hydrothorax to the level of IV rib in the anterior ori-
entation. In comparison with an X-ray conducted few 
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effect. Shortly after infusion began, patient was 
mostly unconscious with the moments of shallow 
sleep. The level of anxiety was reduced and patient 
remained calm. One day later the patient died in 
her sleep, primary cause of death was respirato-
ry failure.
Discussion
Dyspnea remains a significant challenge in pallia-
tive and supportive care; hence, there is still a need to 
find a new or improve the existing ways to alleviate 
this symptom. In compare to the treatment of pain, 
breathlessness therapy remains limited. The clinicians 
are using a few effective groups of drugs, from which 
opioids and benzodiazepines play a crucial role when 
all other treatment methods are exhausted [1]. In the 
presented patient the treatment schedule included 
differential diagnosis, as the dyspnea deterioration 
had multiple origins: mechanical restriction of lungs 
by pleural fluid and metastases, cardiogenic — caused 
by heart tamponade, potential obturation due to 
COPD exacerbation, and lymphangitis carcinomatosis 
syndrome [5]. The multidisciplinary board made the 
difficult decision of aggressive treatment due to few 
important clinical factors that suggested potential 
chemosensitivity: chemo-naïve cancer, rapid progres-
sion of the disease (suggest high mitotic index), good 
performance status shortly before cancer relapse and 
young age of the patient [6, 7]. 
Nevertheless, to start cytostatic treatment pa-
tient’s general status had to be stabilized, thus multi-
ple invasive procedures were conducted. The present-
ed case addresses therapeutic challenges occurring 
when different causes of dyspnea coexist. However 
almost all mentioned causes were induced by cancer 
progression. The oncological board decided to start 
salvage chemotherapy, which was at high risk due to 
poor general condition of the patient. Cytostatic treat-
ment is a gold standard in the chemotherapy-naïve 
metastatic breast cancer, particularly in symptomatic 
pulmonary metastases or lymphangitis carcinoma-
tosis syndrome. Unfortunately, treatment failed to 
reach it’s goals: alleviation of symptoms and further 
stabilization of the disease, despite the potentially 
chemosensitive tumour.
Lymphangitis carcinomatosis is a  rare clinical 
state in which the malignant cells are infiltrating 
the lymphatics. The appearance of the syndrome has 
been reported in skin [8], duodenum [9] and lungs 
[4]. In the pulmonary manifestation the most pre-
dominant symptom is intense breathlessness that 
cannot be relieved by standard procedures [4]. Pri-
mary tumours are typically adenocarcinoma located 
most commonly in breast, stomach, colon, pancreas, 
thyroid, cervix and prostate. Clinical diagnosis is 
currently based on the chest X-ray and High-Reso-
lution Computed Tomography often confirmed by 
histopathological examination of biopsy-derived 
tissue [10]. In addition to symptomatic management 
standard treatment relies on chemotherapy [11], 
which is usually the only causative treatment3. It 
should also be noted that this type of patient is 
often in poor performance status with poor prog-
nosis and choice of chemotherapy regimen might 
be challenging.
This patient was provided with the multidisci-
plinary team care. The holistic approach gave the op-
portunity for adequate treatment both causative and 
symptomatic. In the case of chemotherapy-naïve and 
chemotherapy sensitive advance cancer this treatment 
type gives the best results, even in patients with poor 
performance status. Based on available clinical data 
it was assumed the potentially high chemosensitivity 
of cancer. Unfortunately, the applied treatment was 
ineffective probably due to late implementation of 
individual cytostatic resistance. After exhausting all 
therapeutic options palliative sedation was instituted 
due to the intense shortness of breath and severe 
anxiety, which are the most common indications for 
this procedure [3].
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